

AMGEN

One Amgen Center Drive
Thousand Oaks, CA 91320
(805) 447-1000

~~Official copy~~ gw

~~(Fax)~~ 12/5/00

Telecopier Number: (805) 447-1090

DATE: December 5, 2000

TO: Examiner Joseph Woitach
Patent and Trademarks

FAX #: (703) 308-8724

FROM: Robert B. Winter

DIRECT DIAL #: (805) 447-2425

There are a total of **3** pages being transmitted. If all of the pages are not received, please contact us. Thank you.

COMMENTS:

Serial No: 08/974,186
Applicant: Boyle et al.
Date Filed: November 18, 1997
Docket No.: A-378D5C

This transmission may contain confidential and/or privileged information intended solely for the addressee. If you are not the addressee, any disclosure or use of this information by you is strictly prohibited. If you have received this facsimile in error, please notify us immediately by calling (805) 447-5905.

PATENT APPLICATIONIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Boyle et al.

Serial No.: 08/974,186

Group Art Unit No.: 1632

Filed: November 18, 1997

Examiner: Woltach, J.

For: OSTEOPROTEGERIN

Docket No.: A-378D5C

DRAFT AMENDMENT AFTER FINAL
FOR DISCUSSION ONLYAssistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Please amend the application as follows:

In the claims:

49. (amended) A method of ^{administering to} increasing [regulating] levels of osteoprotegerin in a mammal [an animal] comprising ^{modifying the} ~~the~~ mammal [animal] with a nucleic acid encoding osteoprotegerin, ^{wherein said nucleic acid}

51. (amended) The method of Claim 49 wherein the mammal [animal] is a human.

52. (amended) The method of Claim 51 wherein the nucleic acid encodes osteoprotegerin comprising [comprises] the amino acid sequence as shown in Figure 9B (SEQ ID NO: 5).

53. (amended) The method of Claim 51 wherein the nucleic acid encodes osteoprotegerin comprising [comprises] ^{of amino acids 160-401} a deletion or carboxy-terminal truncation of the amino acid sequence as shown in Figure 9B (SEQ ID NO: 5).

REMARKS

Deletions and carboxy terminal truncations of osteoprotegerin (OPG) are disclosed at p. 15, lines 5-22 of the specification. An example of OPG truncated after residue 180 is set forth in Example 6, starting on p. 37, of the specification. Carboxy terminal truncations of OPG are also described in Example 7, starting on page 49, and in Example 11, starting on page 105, of U.S. Serial No. 08/706,945, filed September 3, 1996, which is a continuation-in-part application of U.S. Serial No. 08/577,788, filed December 22, 1995. The '788 application is the parent application of the instant case.

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below:

December 5, 2000
DateD. Dillon